ArticleRheumatic diseases clinics of North America2010
Cell-bound complement biomarkers for systemic lupus erythematosus: from benchtop to bedside.
Article in Rheumatic diseases clinics of North America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 35 citations in OpenAlex.
- Cutting edge of genetically modified pigs targeting complement activation for xenotransplantation.Frontiers in immunology · 2024Review
- Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progression.Lupus science & medicine · 2020Observational
- Value of combined detection of anti-nuclear antibody, anti-double-stranded DNA antibody and C3, C4 complements in the clinical diagnosis of systemic lupus erythematosus.Experimental and therapeutic medicine · 2019Article
- Potential Roles of Antiphospholipid Antibodies in Generating Platelet-C4d in Systemic Lupus Erythematosus.Antibodies (Basel, Switzerland) · 2017Article
- Cell-bound complement activation products in SLE.Lupus science & medicine · 2017Review
- Article
- SLE and Serum Complement: Causative, Concomitant or Coincidental?The open rheumatology journal · 2017Article
- The Avise Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus.The open rheumatology journal · 2016Article
- Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune Diseases.Frontiers in immunology · 2016Review
- Biomarkers in systemic lupus erythematosus: challenges and prospects for the future.Therapeutic advances in musculoskeletal disease · 2013Article
- Use of biomarkers in the management of children with lupus.Current rheumatology reports · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Systemic lupus erythematosus is arguably the most clinically and serologically diverse autoimmune disease. This article highlights the biomarkers helpful in diagnosing this disease. The authors' own research is presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.